Your browser doesn't support javascript.
loading
The developmental transcription factor IRF6 attenuates ABCG2 gene expression and distinctively reverses stemness phenotype in nasopharyngeal carcinoma.
Xu, Liang; Huang, Tie-Jun; Hu, Hao; Wang, Meng-Yao; Shi, Si-Mei; Yang, Qin; Lin, Fen; Qiang, Yuan-Yuan; Mei, Yan; Lang, Yan-Hong; Li, Chang-Zhi; Peng, Li-Xia; Zheng, Li-Sheng; Huang, Jia-Ling; Li, Xin-Jian; Zhang, Shi-Jun; Qian, Chao-Nan; Huang, Bi-Jun.
Afiliação
  • Xu L; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Huang TJ; Department of Nuclear Medicine, The Second People's Hospital of Shenzhen, Shenzhen, China.
  • Hu H; Department of Traditional Chinese Medicine, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
  • Wang MY; Radiotherapy Department, Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, China.
  • Shi SM; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Yang Q; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Lin F; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Qiang YY; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Mei Y; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Lang YH; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Li CZ; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Peng LX; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Zheng LS; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
  • Huang JL; Department of Pathology, Saint Barnabas Medical Center, Livingston, NJ, USA.
  • Li XJ; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, TX, USA.
  • Zhang SJ; Department of Traditional Chinese Medicine, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
  • Qian CN; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China; Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, Guangzhou, China. Electroni
  • Huang BJ; Department of Experimental Research, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China. Electronic address: huangbj@sysucc.org.cn.
Cancer Lett ; 431: 230-243, 2018 09 01.
Article em En | MEDLINE | ID: mdl-29111349
Nasopharyngeal carcinoma (NPC), which originates from the nasopharynx, is highly prevalent in Southern China and Southeast Asia, and more than 90% of all NPCs are non-keratinizing undifferentiated cells or poorly differentiated squamous cells. Cancer stem cells (CSCs) are capable of self-renewal and have differentiation potential. These properties form the basis of cancer initiation, development, and radiochemoresistance. However, the molecular mechanisms underlying NPC CSC maintenance remain poorly understood. Here, genomic expression profiling using our previously established monoclonal cellular and animal models revealed that interferon regulatory factor 6 (IRF6) was downregulated in highly metastatic NPC cells, cancer stem-like NPC cells and animal models. Functional assays revealed that elevated IRF6 expression suppressed cell proliferation, growth, CSCs properties and enhanced cell chemotherapeutic sensitivity. However, silencing IRF6 resulted in opposing effects. Moreover, we determined that as a tumor suppressor gene and transcription factor, IRF6 directly bound the upstream region of the ATP-binding cassette sub-family G member 2 (ABCG2) DNA element and suppressed target ABCG2 expression in NPC cells. Consistently, an inverse correlation was observed between the mRNA levels of IRF6 and ABCG2 in clinical NPC samples. With these results, we provide the first evidence that IRF6 directly targets the ABCG2 gene and selectively kills CSCs in NPC and that IRF6 may be a valuable tool for developing new CSC-targeted treatment strategies for undifferentiated NPC patients.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fatores Reguladores de Interferon / Membro 2 da Subfamília G de Transportadores de Cassetes de Ligação de ATP / Carcinoma Nasofaríngeo / Proteínas de Neoplasias / Antineoplásicos Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fatores Reguladores de Interferon / Membro 2 da Subfamília G de Transportadores de Cassetes de Ligação de ATP / Carcinoma Nasofaríngeo / Proteínas de Neoplasias / Antineoplásicos Idioma: En Ano de publicação: 2018 Tipo de documento: Article